Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug

European Journal of Neurology

Volumn 11, Issue 9, 2004, Pages 593-606

  Brusa, L ^a,b   Bassi, A ^b   Lunardi, G ^c   Fedele, E ^d   Peppe, A ^b   Stefani, A ^a   Pasqualetti, P ^e   Stanzione, P ^a,b   Pierantozzi, M ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c Dipto di Medicina Sperimentale   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Delayed administration; Entacapone; L dopa pharmacokinetic; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; LEVODOPA;

ADD ON THERAPY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBIDOPA; CATECHOLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG RESISTANCE; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 4644230085     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2004.00860.x     Document Type: Article

References (15)

1. Daniel SE, Lees AJ (1993). Parkinson's Disease Society Brain Bank, London: overview and research. Journal Neural Transmission 39 (suppl):165-172.
2. Davis TL, Brughitta G, Baronti F, Mouradian MM (1991). Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 41:630-633.
3. Fahn S, Elton RL (1987). UPDRS Development Committee. Unified Parkinson's disease rating Scale. In: Fahn S, Marsden CD, Calne D, Golstein M eds. Recent Developments in Parkinson's Disease. MacMillan Healthcare Information, Florham Park, NY, pp. 153-163, 293-304.
4. Heikkinen H, Nutt JG, Le Witt PA, Koller WC, Gordin A (2001). The effect of different repeated doses of entacapone on the pharmacokinetics of L-dopa and on the clinical response to L-dopa in Parkinson's disease. Clin Neuropharmacol 24:150-157.
5. Kaakkola S, Teravainen H, Ahtila S et al. (1994). Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44:77-80.
6. Kaakkola S, Teravainen H, Ahtila S et al. (1995). Entacapone in combination with standard or controlled release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurology 2:341-357.
7. Keranen T, Gordin A, Harjola VP et al. (1993). The effect of catechol-O-methyltransferase inhibition by entacapone on pharmacokinetics and metabolism of L-dopa in healthy volunteers. Clin Neuropharmacol 16:145-156.
8. Keränen T, Gordin A, Karlsson M et al. (1994). Inhibition of soluble catechol-O-methyltransferase and single dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 46:145-156.
9. Merello M, Lees AJ, Webster R et al. (1994). Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson disease. J Neurol Neurosurg Psychiatry 57:186-189.
10. Myllyla W, Sotaniemi LA, Illi A et al. (1993). Effect of entacapone a COMT inhibitor, on the pharmacokinetics of levodopa and cardiovascular responses in patients with Parkinson's disease. Eur J Clin Neuropharmacol 45:419-423.
11. Nutt JG, Woodward WR, Beckner RM et al. (1994). Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44:913-919.
12. Oscarson M (2003) Pharmacogenetics of drug metabolizing enzymes: importance for personalized medicine. Clin Chem Lab Med 41:573-580.
13. Pierantozzi M, Pietroiusti A, Galante A et al. (2001). Helicobacter pylori-induced reduction of acute levodopa absorption in Parkinson's disease patients. Ann Neurol 50:686-687.
14. Ruottinen HM, Rinne UK (1996a). A double blind pharmacokinetic and clinical dose-response study of entacapone as an adjunct to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 19:283-296.
15. Ruottinen HM, Rinne UK (1996b). Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 19:222-233.